ArticleNature communications2025
Fe(OTf)3 or Photosensitizer-free blue light activated diazo-thioglycoside donors for Iterative and stereoselective glycosylations.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Conventional methods for thioglycoside activation often rely on precious and toxic platinum group metals. Here, we report a catalytic glycosylation strategy employing diazo-thioglycoside donors activated by earth-abundant iron or photosensitizer-free blue light conditions. It confers orthogonal reactivity relative to most glycosyl donors, including widely used thioglycosides and alkyne-based donors, thereby enabling one-pot orthogonal synthesis of glycans. The Thorpe-Ingold-like effect drives the proximity of iron- or blue-light-generated carbenes to the sulfur atom of thioglycosides. This approach accommodates diverse protecting groups and nucleophiles. It applies to various glycosyl donors derived from glucose, mannose, galactose, rhamnose, xylose, lactose, 2-deoxyamino glucose, and furanose derivatives such as ribose and arabinose. Moreover, we demonstrate the robustness of this methodology through challenging 1,2-cis furanosides, late-stage modifications of biomolecules like cholesterol, and the drug simvastatin on a gram scale, along with the iterative synthesis of challenging hexasaccharides.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.